Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 14/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753611 | 0.93 | AGTR1 (0.42) | AGTR1LTB4R2AGTR2ABCB11GP6 | |
| SCHEMBL3744496 | 0.92 | MC4R (0.43) | AGTR1LTB4R2AGTR2MC4RMC5R | |
| SCHEMBL10197324 | 0.88 | AGTR1 (0.43) | AGTR1LTB4R2AGTR2MC4RMC5R | |
| SCHEMBL11896872 | 0.88 | MC4R (0.48) | AGTR1LTB4R2AGTR2MC4RMC5R | |
| SCHEMBL489651 | 0.87 | MC4R (0.40) | AGTR1LTB4R2AGTR2MC4RMC5R | |
| SCHEMBL9429547 | 0.85 | LTB4R2 (0.47) | AGTR1LTB4R2AGTR2ABCB11GP6 | |
| SCHEMBL3753609 | 0.85 | AGTR1 (0.42) | AGTR1LTB4R2AGTR2ABCB11GP6 | |
| SCHEMBL489225 | 0.83 | AGTR1 (0.39) | AGTR1LTB4R2AGTR2ABCB11GP6 | |
| SCHEMBL3748641 | 0.83 | AGTR1 (0.62) | AGTR1LTB4R2AGTR2ABCB11GP6 | |
| SCHEMBL3127027 | 0.83 | LTB4R2 (0.45) | AGTR1LTB4R2AGTR2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009035543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-03-19 | — | — | WO | disclosed |